Ypsomed Holding AG (YPSN) AI Stock Analysis

• Market Cap: CHF5.60B
• Dividend Yield: 0.49%
• Average Volume (3M): 16.43K
• Price to Earnings (P/E): 63.9
• Beta (1Y): 0.68
• Revenue Growth: 21.33%
• EPS Growth: 2.72%
• Country: CH
• Employees: 2,600
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 4.02
• Shares Outstanding: 13,649,739
• 10 Day Avg. Volume: 17,747
• 30 Day Avg. Volume: 16,432
• PEG Ratio: 0.46
• Price to Book (P/B): 4.59
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -65.13
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF430.33
• Price Target Upside: 4.96% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 60 Neutral
• Price Target: ―

Ypsomed Holding AG's strength lies in its solid financial performance with strong revenue growth and profitability. However, the stock faces challenges with an overvaluation and moderate technical indicators. The lack of recent earnings guidance or corporate events leaves the focus on improving cash flow management to drive future growth.

Ypsomed Holding AG Business Overview & Revenue Model

Company Description

Ypsomed Holding AG (YPSN) is a Swiss-based company engaged in the development and manufacturing of injection and infusion systems for self-medication, with a focus on diabetes management. It operates in the medical technology sector, providing innovative solutions for insulin delivery and other therapeutic areas. The company offers a range of products, including insulin pumps, pen injectors, and related accessories, catering to both healthcare professionals and patients.

How the Company Makes Money

Ypsomed Holding AG generates revenue primarily through the sale of its medical devices and solutions for self-medication. Key revenue streams include the direct sale of insulin pumps, pen injectors, and infusion sets, as well as the provision of related services. The company also licenses its technology to pharmaceutical companies, which contributes to its earnings. Significant partnerships with global pharmaceutical companies enhance its market reach and product distribution, further driving revenue growth. Ypsomed's focus on innovation and expanding its product portfolio supports its financial performance in the competitive medical technology industry.

Ypsomed Holding AG Financial Statement Overview

Summary

Ypsomed Holding AG exhibits strong financial performance with robust revenue growth and profitability. The balance sheet reflects stability with low leverage, though improvement is needed in cash flow generation, particularly in free cash flow management.

Income Statement

Ypsomed Holding AG has shown a strong performance in its income statement with a notable revenue growth rate of 10.24% from 2023 to 2024. The gross profit margin stands at a healthy 34.47%, and the net profit margin is 14.29%, indicating efficient cost management and profitability. EBIT and EBITDA margins are also robust at 15.72% and 29.5%, respectively. The consistent revenue growth and profitability reflect a positive trajectory for the company.

Balance Sheet

The balance sheet of Ypsomed Holding AG shows a solid equity base with an equity ratio of 56.09%, highlighting financial stability. The debt-to-equity ratio is 0.41, which is relatively low and indicates conservative leverage. However, the return on equity (ROE) of 12.69% suggests moderate efficiency in using equity capital to generate profits. Overall, the balance sheet is stable but has room for improvement in maximizing returns on equity.

Cash Flow

Ypsomed Holding AG's cash flow statement reveals a mixed picture. The operating cash flow to net income ratio is 2.08, demonstrating strong cash generation relative to its net income. However, the free cash flow growth rate remains negative, and the free cash flow to net income ratio is -0.41, indicating a need to improve capital expenditure management to enhance free cash flow.

Breakdown	TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement
Total Revenue	617.07M	548.46M	497.46M	464.84M	403.66M	394.26M
Gross Profit	218.66M	189.05M	140.59M	113.82M	94.83M	90.97M
EBITDA	145.13M	161.78M	137.51M	92.48M	63.86M	61.63M
Net Income	74.39M	78.37M	51.27M	23.11M	5.81M	11.73M
Balance Sheet
Total Assets	1.18B	1.10B	861.88M	756.91M	717.68M	678.24M
Cash, Cash Equivalents and Short-Term Investments	52.31M	74.02M	25.22M	17.04M	22.41M	22.33M
Total Debt	325.19M	256.00M	157.00M	267.00M	215.00M	193.00M
Total Liabilities	559.11M	483.66M	291.57M	356.63M	313.54M	292.89M
Stockholders Equity	621.87M	617.74M	562.33M	392.54M	395.38M	377.66M
Cash Flow
Free Cash Flow	-8.12M	-32.09M	-39.64M	-41.72M	-40.75M	-69.64M
Operating Cash Flow	156.69M	163.22M	129.53M	85.71M	85.83M	49.09M
Investing Cash Flow	-234.23M	-195.07M	-122.02M	-125.70M	-106.91M	-115.83M
Financing Cash Flow	94.35M	81.07M	1.26M	38.12M	26.67M	68.66M

Ypsomed Holding AG Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 410.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:YPSN, the sentiment is Positive. The current price of 410 is above the 20-day moving average (MA) of 406.50, above the 50-day MA of 371.45, and above the 200-day MA of 370.10, indicating a bullish trend. The MACD of 9.70 indicates Positive momentum. The RSI at 65.92 is Neutral, neither overbought nor oversold. The STOCH value of 60.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:YPSN.

Ypsomed Holding AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SFZN	75 Outperform	$4.11B	24.53	18.36%	4.51%	1.82%	39.11%
MOVE	66 Neutral	$2.64B	38.09	20.81%	0.42%	13.35%	50.65%
Sector *	63 Neutral	CHF22.54B	15.19	10.81%	2.10%	47.85%	-11.82%
TECN	63 Neutral	CHF2.06B	30.34	4.84%	1.86%	-13.04%	-48.74%
YPSN	60 Neutral	CHF5.60B	63.95	13.49%	0.49%	21.33%	2.72%